|
1
|
Forman D, Bray F and Brewster D: Cancer
Incidence in Five Continents Vol X (eletronic version). IARC; Lyon:
2013, http://ci5.iarc.fr/Default.aspx.
Accessed January 2, 2014
|
|
2
|
Zappasodi R, de Braud F and Di Nicola M:
Lymphoma immunotherapy: Current status. Front Immunol. 6:4482015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brandt CS, Baratin M, Yi EC, Kennedy J,
Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et
al: The B7 family member B7-H6 is a tumor cell ligand for the
activating natural killer cell receptor NKp30 in humans. J Exp Med.
206:1495–1503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou Y, Xu Y, Chen L, Xu B, Wu C and Jiang
J: B7-H6 expression correlates with cancer progression and
patient's survival in human ovarian cancer. Int J Clin Exp Pathol.
8:9428–9433. 2015.PubMed/NCBI
|
|
5
|
Wu MR, Zhang T, DeMars LR and Sentman CL:
B7H6-specific chimeric antigen receptors lead to tumor elimination
and host antitumor immunity. Gene Ther. 22:675–684. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Semeraro M, Rusakiewicz S, Minard-Colin V,
Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C,
Ponzoni M, et al: Clinical impact of the NKp30/B7-H6 axis in
high-risk neuroblastoma patients. Sci Transl Med. 7:283ra552015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kellner C, Maurer T, Hallack D, Repp R,
van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M and
Peipp M: Mimicking an induced self phenotype by coating lymphomas
with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J
Immunol. 189:5037–5046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu MR, Zhang T, Gacerez AT, Coupet TA,
DeMars LR and Sentman CL: B7H6-specific bispecific T cell engagers
lead to tumor elimination and host antitumor immunity. J Immunol.
194:5305–5311. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mir MA and Agrewala JN: Signaling through
CD80: An approach for treating lymphomas. Expert Opin Ther Targets.
12:969–979. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Philips GK and Atkins M: Therapeutic uses
of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 27:39–46.
2015. View Article : Google Scholar
|
|
11
|
Leung J and Suh WK: The CD28-B7 family in
anti-tumor immunity: Emerging concepts in cancer immunotherapy.
Immune Netw. 14:265–276. 2014. View Article : Google Scholar :
|
|
12
|
Seliger B and Quandt D: The expression,
function, and clinical relevance of B7 family members in cancer.
Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Wang Y, Wang J, Dong F, Zhu M,
Wan W, Li H, Wu F, Yan X and Ke X: B7-H3 silencing inhibits tumor
progression of mantle cell lymphoma and enhances chemosensitivity.
Int J Oncol. 46:2562–2572. 2015.PubMed/NCBI
|
|
14
|
Li Y, Wang J, Li C and Ke XY: Contribution
of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting
therapy. Leuk Lymphoma. 53:2015–2023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaifu T, Escalière B, Gastinel LN, Vivier
E and Baratin M: B7-H6/NKp30 interaction: A mechanism of alerting
NK cells against tumors. Cell Mol Life Sci. 68:3531–3539. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang T, Wu MR and Sentman CL: An
NKp30-based chimeric antigen receptor promotes T cell effector
functions and antitumor efficacy in vivo. J Immunol. 189:2290–2299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schlecker E, Fiegler N, Arnold A, Altevogt
P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann
EP, Textor S, et al: Metalloprotease-mediated tumor cell shedding
of B7-H6, the ligand of the natural killer cell-activating receptor
NKp30. Cancer Res. 74:3429–3440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fiegler N, Textor S, Arnold A, Rölle A,
Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M and Cerwenka A:
Downregulation of the activating NKp30 ligand B7-H6 by HDAC
inhibitors impairs tumor cell recognition by NK cells. Blood.
122:684–693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen XJ, Shen J, Zhang GB and Chen WC:
B7-H6 protein expression has no prognostic significance in human
gastric carcinoma. Pathol Oncol Res. 20:203–207. 2014. View Article : Google Scholar
|
|
20
|
Zhang X, Zhang G, Qin Y, Bai R and Huang
J: B7-H6 expression in non-small cell lung cancers. Int J Clin Exp
Pathol. 7:6936–6942. 2014.PubMed/NCBI
|
|
21
|
Baran-Marszak F, Boukhiar M, Harel S,
Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank
N, Ajchenbaum-Cymbalista F, et al: Constitutive and B-cell
receptor-induced activation of STAT3 are important signaling
pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Haematologica. 95:1865–1872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Munoz J, Dhillon N, Janku F, Watowich SS
and Hong DS: STAT3 inhibitors: Finding a home in lymphoma and
leukemia. Oncologist. 19:536–544. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soldini D, Montagna C, Schüffler P, Martin
V, Georgis A, Thiesler T, Curioni-Fontecedro A, Went P, Bosshard G,
Dehler S, et al: A new diagnostic algorithm for Burkitt and diffuse
large B-cell lymphomas based on the expression of CSE1L and STAT3
and on MYC rearrangement predicts outcome. Ann Oncol. 24:193–201.
2013. View Article : Google Scholar
|
|
24
|
Lu S, Gao Y, Huang X and Wang X: GYY4137,
a hydrogen sulfide (H2S) donor, shows potent
anti-hepatocellular carcinoma activity through blocking the STAT3
pathway. Int J Oncol. 44:1259–1267. 2014.PubMed/NCBI
|
|
25
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He C, Liu Z, Ji J and Zhu H: Prognostic
value of survivin in patients with non-Hodgkin's lymphoma: A
meta-analysis. Int J Clin Exp Med. 8:5847–5854. 2015.PubMed/NCBI
|
|
27
|
Wang SC: PCNA: A silent housekeeper or a
potential therapeutic target? Trends Pharmacol Sci. 35:178–186.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Said J, Lones M and Yea S: Burkitt
lymphoma and MYC: What else is new? Adv Anat Pathol. 21:160–165.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brinkmann K and Kashkar H: Targeting the
mitochondrial apoptotic pathway: A preferred approach in
hematologic malignancies? Cell Death Dis. 5:e10982014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hardwick JM and Soane L: Multiple
functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol.
5:a87222013. View Article : Google Scholar
|
|
31
|
Shalini S, Dorstyn L, Dawar S and Kumar S:
Old, new and emerging functions of caspases. Cell Death Differ.
22:526–539. 2015. View Article : Google Scholar
|
|
32
|
Yang WJ, Yu Z and Qiu LG: Research
advances of signal pathway in the pathogenesis of mantle cell
lymphoma. Zhonghua Xue Ye Xue Za Zhi. 34:1073–1075. 2013.(In
Chinese). PubMed/NCBI
|
|
33
|
Bonn BR, Krieger D and Burkhardt B: Cell
cycle regulatory molecular profiles of pediatric T-cell
lymphoblastic leukemia and lymphoma. Leuk Lymphoma. 53:557–568.
2012. View Article : Google Scholar
|
|
34
|
Tamura K: Development of cell-cycle
checkpoint therapy for solid tumors. Jpn J Clin Oncol.
45:1097–1102. 2015.PubMed/NCBI
|
|
35
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Migliaccio I, Di Leo A and Malorni L:
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.
Curr Opin Oncol. 26:568–575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dutto I, Tillhon M, Cazzalini O, Stivala
LA and Prosperi E: Biology of the cell cycle inhibitor p21(CDKN1A):
Molecular mechanisms and relevance in chemical toxicology. Arch
Toxicol. 89:155–178. 2015. View Article : Google Scholar
|
|
38
|
Hazar B, Polat G, Seyrek E, Bağdatoğlğlu
O, Kanik A and Tiftik N: Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's
lymphoma. Int J Clin Pract. 58:139–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Suminoe A, Matsuzaki A, Hattori H, Koga Y,
Ishii E and Hara T: Expression of matrix metalloproteinase (MMP)
and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute
lymphoblastic leukemia with organ involvement. Leuk Res.
31:1437–1440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiong A, Yang Z, Shen Y, Zhou J and Shen
Q: Transcription factor STAT3 as a novel molecular target for
cancer prevention. Cancers (Basel). 6:926–957. 2014. View Article : Google Scholar
|
